Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003343 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT00003343 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 525 participants.
The verdict
NCT00003343, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether mitoxantrone and prednisone are more effective with or without prinomastat in treating patients with metastatic prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of mitoxantrone and prednisone with or without prinomastat in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG prednisone
- DRUG endocrine-modulating drug therapy
- DRUG mitoxantrone hydrochloride
- DRUG prinomastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 1998-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003343
The ClinicalTrials.gov registry entry for NCT00003343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which prednisone is the first listed.
NCT00003343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003343 about?
NCT00003343 is a clinical study titled "Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether mitoxantrone and prednisone are more effective with or without prinomastat in treating patients with metastatic prostate cancer. PURPOSE: Randomized ph...
What is the current status of trial NCT00003343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00003343?
The interventions under investigation include: prednisone (DRUG), endocrine-modulating drug therapy (DRUG), mitoxantrone hydrochloride (DRUG), prinomastat (DRUG).
Who is sponsoring clinical trial NCT00003343?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.